Pharmacokinetics of omega-3 fatty acids in patients with severe sepsis compared with healthy volunteers: A prospective cohort study

Objective This study aimed to evaluate the dose-response effects of supplemental omega-3 fatty acids on platelet function in healthy volunteers. Methods Twelve healthy volunteers ingested a normal supplemental dose of 1260 mg omega-3 fatty acids daily for 5 days, followed by a high dose of 2520 mg daily for another 5 days. Multiple electrode aggregometry (MEA) with four different agonists was used to measure platelet aggregation before and after the normal- and high-dose regimes. In vitro spiking using physiological doses of omega-3 fatty acids was also performed to determine whether MEA is capable of detecting a platelet-inhibiting effect due to omega-3 fatty acids. Results There were no differences in platelet aggregation measured by the MEA assay in healthy volunteers after intake of either the normal or high dose of omega-3 fatty acids. In the in vitro experiment, a platelet-inhibiting effect of omega-3 fatty acids was shown by an arachidonic acid agonist in MEA . Conclusions Supplemental omega-3 fatty acids do not evoke their positive health effects through inhibition of platelet aggregation measurable with MEA.

Download Full-text

The role of fatty acids on ICSI outcomes: a prospective cohort study

Lipids in Health and Disease ◽

10.1186/s12944-016-0396-z ◽

2017 ◽

Vol 16 (1) ◽

Cited By ~ 20

Author(s):

Parvaneh Mirabi ◽

Mohammad Javad Chaichi ◽

Sedighe Esmaeilzadeh ◽

Seyed Gholam Ali Jorsaraei ◽

Ali Bijani ◽

...

Keyword(s):

Fatty Acids ◽

Cohort Study ◽

Prospective Cohort Study ◽

Prospective Cohort ◽

Icsi Outcomes

Download Full-text

High-dose omega-3 fatty acids have no effect on platelet aggregation or coagulation measured with static and flow-based aggregation instruments and Sonoclot; an observational study in healthy volunteers

Scandinavian Journal of Clinical and Laboratory Investigation ◽

10.1080/00365513.2018.1516477 ◽

2018 ◽

Vol 78 (7-8) ◽

pp. 539-545 ◽

Cited By ~ 4

Author(s):

August Bagge ◽

Ulf Schött ◽

Thomas Kander

Keyword(s):

Fatty Acids ◽

Platelet Aggregation ◽

Observational Study ◽

Healthy Volunteers ◽

High Dose ◽

Omega 3 Fatty Acids ◽

Omega 3

Download Full-text

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

Thrombosis and Haemostasis ◽

10.1160/th15-03-0192 ◽

2015 ◽

Vol 114 (07) ◽

pp. 198-205 ◽

Cited By ~ 84

Author(s):

Paul A. Reilly ◽

Richard Bernstein ◽

Robert Dubiel ◽

John Eikelboom ◽

Stephan Glund ◽

...

Keyword(s):

Cohort Study ◽

Healthy Volunteers ◽

Prospective Cohort Study ◽

Prospective Cohort ◽

Reversal Agent ◽

Fab Fragment ◽

Phase 3 ◽

Urgent Surgery ◽

Complete Reversal ◽

Life Threatening

SummaryIdarucizumab, a Fab fragment directed against dabigatran, produced rapid and complete reversal of the anticoagulation effect of dabigatran in animals and in healthy volunteers. The Study of the REVERS al E ffects of Idarucizumab in Patients on A ctive D abigatran (RE-VERSE AD™) is a global phase 3 prospective cohort study aimed at investigating idarucizumab in dabigatran-treated patients who present with uncontrollable or life-threatening bleeding, and in those requiring urgent surgery or intervention. We describe the rationale for, and design of the trial (clinicaltrials.gov NCT02104947).

Download Full-text